An experimental Novo Nordisk drug for cardiovascular diseases, the IL-6 inhibitor ziltivekimab, has failed the phase 3 ZEUS ...

There are rumours that a pharma 'mega-merger' – between AstraZeneca and Bristol Myers Squibb – is in the offing, ending several years without this type of deal. A report in the Financial Times ...

A cannabis-derived drug developed by Germany's Vertanical has shown efficacy in phase 3 as a treatment for chronic pain, offering the prospect of an alternative to opioid drugs that carry the risk of ...

Sanofi said this morning that its pipeline includes 12 potential blockbuster drugs that could generate more than €10 billion ($11 billion) in annual sales by the end of the decade, a sharp increase on ...

At its second attempt, Rocket Pharma has won FDA approval for its gene therapy for severe leukocyte adhesion deficiency type I (LAD-I), a rare and life-threatening immune disorder that leaves patients ...

Novartis has claimed accelerated approval from the FDA for Vanrafia, one of a trio of therapies it hopes will revolutionise the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia ...

As Ozempic and other GLP-1 drugs explode in popularity, driven by their off-label use for rapid weight loss and viral social media trends, the pharmaceutical industry faces unprecedented challenges.

After three knockbacks by the FDA, Outlook Therapeutics has finally pushed its therapy for wet age-related macular ...

Agios Pharma has said it will halt clinical development of tebapivat, a PK activator that had reached phase 2 testing in ...

Scribe Therapeutics has become the latest biotech to list on the Nasdaq in the US, raising more than $155 million to advance ...

According to a letter (PDF) signed by US Senators Elizabeth Warren (D-Mass), Angela Alsobrooks (D-Md), Richard Blumenthal ...

A dual GLP-1 and glucagon agonist developed by Altimmune has been shown to reduce drinking in people with alcohol use ...